Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients

Oral Oncology

Volumn 45, Issue 2, 2009, Pages 164-172

  Sonis, Stephen T ^a,b   Watkins, Brynmor A ^d   Lyng, Gregory D ^d   Lerman, Mark A ^a,b   Anderson, Kenneth C ^a,c  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Biomodels LLC   (United States)

Author keywords

Animal model; Bisphosphonates; Dental extractions; Jaw; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; ZOLEDRONIC ACID;

ALVEOLAR RIDGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE NECROSIS; CANCER PATIENT; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITY; EPITHELIUM CELL; EPITHELIZATION; FEMALE; HEALING; HISTOLOGY; INFLAMMATORY INFILTRATE; JAW; JAW OSTEONECROSIS; MANDIBLE; MAXILLA; NONHUMAN; PATHOGENESIS; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; RADIOGRAPHY; RAT; SOFT TISSUE; SPRAGUE DAWLEY RAT; TOOTH EXTRACTION; VASCULARIZATION;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DEXAMETHASONE; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MANDIBULAR DISEASES; MAXILLARY DISEASES; ORAL ULCER; OSTEONECROSIS; PROSPECTIVE STUDIES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 58549091291     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.04.013     Document Type: Article

References (22)

1. Dunstan C.R., Felsenberg D., and Seibel M.J. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4 (2007) 42-55
2. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 7 Suppl. 1 (2007) S14-S25
3. Luftner D., Henschke P., and Possinger K. Clinical value of bisphosphonates in cancer therapy. Anticancer Res 27 (2007) 1759-1768
4. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
5. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (Bis-Phossy Jaw: Is this Phossy Jaw of the 21st Century?. J Oral Maxillofac Surg 63 (2005) 682-689
6. Bagan J.V., Murillo J., Jimenez Y., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34 (2005) 120-123
7. Ruggiero S.L., Merotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
8. Ficarra G., Beninati F., Rubino I., et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 11 (2005) 1123-1128
9. Hansen T., Kunkel M., Weber A., et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155-160
10. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
11. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479-1491
12. Marx R.E., Cillo J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 65 (2007) 2397-2410
13. Migliorati C.A., Casiglia J., Epstein J., et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 136 (2005) 1658-1668
14. Graziani F., D'Aiuto F., Arduino P.G., et al. Perioperative dexamethasone reduces post-surgical sequelae of wisdom tooth removal. A split-mouth randomized double-masked clinical trial. Int J Oral Maxillofac Surg 35 (2006) 241-246
15. Marx R.E., Sawati Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
16. Ruggiero S.L., and Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86 (2007) 1013-1021
17. Klingenstein G., Levy R.N., Kornbluth A., et al. Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther 21 (2005) 243-249
18. Reid I.R., Bolland M.J., and Gray A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
19. 2 MDP on bone in the rat: in vivo and in vitro studies. Metab Bone Dis Relat Res 2S (1980) 381-387
20. Parfitt J.R., and Driman D.K. Pathological effects of drugs on the gastrointestinal tract: a review. Human Pathol 38 (2007) 527-536
21. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59 (2001) 193-202
22. Moreira M.S., Katayama E., Bombana A.C., et al. Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study. Dent Traumatol 21 (2005) 329-335